(Q45298304)

11 December 2017

title

Clodronate for treatment of bone metastases in hormone refractory prostate cancer (English)

1 reference

11 December 2017

Flavio Hering

1

1 reference

11 December 2017

Paulo R T Rodrigues

series ordinal

2

1 reference

11 December 2017

Marco Lipay

series ordinal

3

1 reference

11 December 2017

publication date

1 May 2003

1 reference

International Brazilian Journal of Urology

11 December 2017

published in

1 reference

11 December 2017

volume

29

1 reference

11 December 2017

issue

3

1 reference

11 December 2017

page(s)

228-233

1 reference

11 December 2017

cites work

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382003000300006

The biology of hormone refractory prostate cancer. Why does it develop?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382003000300006

Complications of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382003000300006

Malignant bone resorption: cellular and biochemical mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382003000300006

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382003000300006

Pathophysiologic interactions in skeletal metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382003000300006

Bisphosphonates and tumor burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382003000300006

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382003000300006

The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1677-55382003000300006

10.1590/S1677-55382003000300006

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference